Perrigo gets tentative approval for generic Soolantra
The Food and Drug Administration has given its tentative approval to Perrigo’s generic Soolantra (ivermectin, 1%) cream. Perrigo said that it has previously settled litigation with Galderma Labs, Galderma SA and Nestle Skin Health for the product.
Perrigo’s generic Soolantra is indicated to treat inflammatory rosacea lesions. The product had U.S. sales of $120 million for the past 12 months, according to IQVIA data. This tentative approval is one in a string of FDA nods Perrigo’s products have received recently.
“This is the Rx team's fifth generic product approval this month,” Perrigo executive vice president and president Rx pharmaceuticals John Wesolowski said. “This tentative approval further illustrates our commitment to advancing our new product pipeline and providing savings to patients and healthcare systems.”
Perrigo’s generic Soolantra is indicated to treat inflammatory rosacea lesions. The product had U.S. sales of $120 million for the past 12 months, according to IQVIA data. This tentative approval is one in a string of FDA nods Perrigo’s products have received recently.
“This is the Rx team's fifth generic product approval this month,” Perrigo executive vice president and president Rx pharmaceuticals John Wesolowski said. “This tentative approval further illustrates our commitment to advancing our new product pipeline and providing savings to patients and healthcare systems.”